Literature DB >> 28133033

[Therapeutic Strategies with Multidisciplinary Local Therapy for Postoperative Recurrence of Esophageal Cancer].

Koichi Okamoto1, Itasu Ninomiya, Atsushi Hirose, Jun Kinoshita, Keishi Nakamura, Katsunobu Oyama, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Sachio Fushida, Tsuyoshi Takanaka, Tetsuo Ohta.   

Abstract

We report our experience with tailored treatment comprising resection or radiotherapy for postoperative recurrence of esophageal cancer in 73 patients(35.4%)who were diagnosed with recurrent esophageal cancer after curative resection. The initial recurrence patterns included 7 patients(3.4%)with local recurrence, 38 patients(18.4%)with lymphatic recurrence, 40 patients(19.4%)with hematologic metastases, and 12 patients(5.8%)with dissemination.Twenty -three patients had solitary lung metastases, and good local control was achieved by surgical resection alone.The success rate of intensity modulated radiation therapy (IMRT) for local control was 64.1%, and IMRT was considered effective and less invasive. The 2-year survival rate after successful treatment for recurrence was 53.5%, vs 5.8% after unsuccessful treatment. Improved prognosis for patients with recurrent esophageal cancer can be expected when adequate local control is achieved according to recurrence pattern by surgical resection or IMRT.

Entities:  

Mesh:

Year:  2016        PMID: 28133033

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  External beam radiotherapy with or without californium-252 neutron brachytherapy for treatment of recurrence after definitive chemoradiotherapy.

Authors:  Wen-An Wu; Yi-Ping Yang; Jing Liang; Jin Zhao; Jian-Sheng Wang; Jia Zhang
Journal:  Sci Rep       Date:  2020-12-01       Impact factor: 4.379

2.  NOTCH3 limits the epithelial-mesenchymal transition and predicts a favorable clinical outcome in esophageal cancer.

Authors:  Norihiro Matsuura; Koji Tanaka; Makoto Yamasaki; Kotaro Yamashita; Takuro Saito; Tomoki Makino; Kazuyoshi Yamamoto; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Hidetoshi Eguchi; Hiroshi Nakagawa; Yuichiro Doki
Journal:  Cancer Med       Date:  2021-05-27       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.